Form 4: Zoetis EVP Kevin Esch Receives Equity Grants

Zoetis Inc. Executive Vice President Kevin Esch was granted 4,026 restricted stock units and 15,931 stock options.

Summary

• Kevin Esch, Executive Vice President of Zoetis Inc. (ZTS), was granted new equity awards.
• The new grants include 4,026 Restricted Stock Units (RSUs) and 15,931 Stock Options.
• The grant date for these new awards is February 18, 2026.
• Each RSU represents a contingent right to receive one share of Zoetis Inc. common stock.
• The RSUs will vest in one-third increments on the first, second, and third anniversaries of the grant date (February 18, 2026), subject to continued service.
• The stock options have an exercise price of $129.13 per share.
• The stock options will vest in one-third increments on the first, second, and third anniversaries of the grant date (February 18, 2026).
• Each stock option expires on the tenth anniversary of its grant date.
• The filing also details previously granted RSUs and stock options with their respective vesting schedules and exercise prices.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive development, as it represents a routine executive compensation grant that aligns management's long-term interests with shareholder value creation.

Positives

• The equity grants align the Executive Vice President's interests with those of shareholders, incentivizing long-term performance.
• The grants are part of a standard equity and incentive plan, indicating ongoing executive compensation practices.

Future Outlook

The grants establish future vesting schedules for equity awards, extending through February 2029 for the newly granted RSUs and stock options, contingent on the reporting person's continued service.

Industry Context

StockSavvy.ai notes that equity grants, such as Restricted Stock Units and stock options, are a common component of executive compensation packages across various industries, including the animal health sector where Zoetis operates. These grants are designed to incentivize long-term performance and align management's financial interests with those of shareholders.

Comparison to Industry Standards

• The structure of these equity grants, with multi-year vesting schedules, is consistent with typical executive compensation practices in large-cap pharmaceutical and animal health companies, aiming to promote retention and long-term value creation.
• While specific grant sizes vary by company, executive role, and performance, the use of both RSUs and stock options is a standard approach to provide a balanced incentive structure, offering both retention value (RSUs) and upside potential (options).

Stakeholder Impact

• Shareholders: The grants align executive incentives with long-term company performance, potentially benefiting shareholders through sustained growth and value creation.
• Employees: The equity compensation structure may serve as a benchmark or incentive model for other employees, influencing overall compensation philosophy.

Next Steps

• One-third of the newly granted Restricted Stock Units will vest on February 18, 2027, February 18, 2028, and February 18, 2029.
• One-third of the newly granted Stock Options will vest on February 18, 2027, February 18, 2028, and February 18, 2029.
• The newly granted Stock Options will expire on February 18, 2036.

Key Dates

Keywords

Zoetis Inc., ZTS, Kevin Esch, Restricted Stock Units, Stock Options, Equity Grant, Insider Transaction, Executive Compensation, Form 4, SEC Filing